ABOUT US

Ken ChengPresident

  • Dongguan Shun Cheng Computer Enteprise Corporation　Director of Board
  • Solytech Enteprise Corporation　President
  • Experiences in R&D and manufacturing departments of electronic components industry management for over 30 years.

Sean Chen Ph.D.General Manager

  • MS/Ph.D., Neuroscience, College of Medicine, Ohio State University, Columbus, USA
  • Research Fellow, Whitehead Institute for Biomedical Research, MIT, Boston, USA
  • Department Head, R&D, Genovate Biotechnology Co., Ltd. Taiwan
  • Founder/Board Director/General Manager, Transwell Biotechnology Co., Ltd. Taiwan
  • Founder/Board Director/GM, Capstone Biotek Inc., Taipei
  • Experiences in Drug development for over 30 years.

Cheng-Wen Lin Ph.D.Chief Scientific Officer

  • Ph.D., Biomedical Engineering, Durham, NC, Duke University
  • Postdoctoral Fellow, Durham, NC, Duke University Eye Center
  • Director of Research (Executive level), Aerie Pharmaceuticals, Inc. (now Alcon)
  • Adjunct Assistant Professor, School of Pharmacy, Morgantown, WV, West Virginia University
  • Chief Scientific Officer, Perfuse Therapeutics, Inc.
  • Experiences in ocular drug research and development for over 15 years
  • Discovered and developed two marketed products (Rhopressa® & Rocklatan®)

Akaphot Thongmee (Mark), M.D.,Chief Medical Officer

Dr. Mark Thongmee, M.D., MRCP (UK), is a translational research physician trained in Translational Medicine and Early Phase Development from Imperial College London.
With over a decade of experience, he has contributed significantly to clinical trials in infectious diseases and oncology across Southeast Asia, including leading community-based trials for HIV and HCV. He has spearheaded numerous research trials and medical initiatives, notably as;

  • Global Medical Affairs lead at GPCRO Contract Research Organisation, leading the clinical trial designed and medical monitor for oncology, ophthalmology, COVID-19 infection, and gene therapy.
  • Country Medical Director at Amgen and Allergan, he bridged clinical research with strategic medical affairs, enhanced drug accessibility, and implemented health economic outcomes research (HEOR) to support reimbursement strategies.

Simon HuangExecutive Vice President

  • NYIT　M.B.A.
  • Barits Securities Corporation　Researcher
  • Solytech Enteprise Corporation　Independent President
  • Taipei Biotech Association　Supervisor
  • Professional experiences in clinical trail over 6 years
  • Professional experiences (including the experiences of the securities industry and the investment company) in financial industry and capital market for over 20 years.

Amy ChenOffice of General Affairs Director& Chief Financial Officer

  • Royal Roads University M.B.A. in Executive Management
  • Wayi International Digital Entertainment Co.,Ltd..　Manager
  • Professional experiences in financial management and fund allocation for over 25 years.

Evelyn WangBusiness Development& Management Department Director

  • National Chung Cheng University M.B.A.
  • PWC Taiwan　Auditor
  • Taipei Fubon Commercial 　Senior Specialist
  • Experiences in financial industry, accounting field, and research on business management for over 10 years.
↑